Gérard Limoges

Aeterna Zentaris, a specialty biopharmaceutical company, is a party to a license and assignment agreement with a subsidiary of Novo Nordisk A/S to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin), an oral ghrelin receptor agonist to be administered in the diagnosis of patients with adult growth hormone deficiency, in the United States and Canada.